F-18 FDG uptake in breast infection and inflammation

Clinical Nuclear Medicine

Volumn 25, Issue 2, 2000, Pages 100-103

  Bakheet, Siema M B ^a   Powe, John ^a   Kandil, Alaa ^a   Ezzat, Adnan ^a   Rostom, Assem ^a   Amartey, John ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Benign Disease; Breast Uptake; False positive Results; Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER STAGING; CASE REPORT; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MASTITIS; RADIOISOTOPE DISTRIBUTION; STAPHYLOCOCCUS AUREUS;

ADULT; BREAST; BREAST DISEASES; BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HEMATOMA; HUMANS; MASTITIS; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; RADIOPHARMACEUTICALS; STAPHYLOCOCCAL INFECTIONS; TOMOGRAPHY, EMISSION-COMPUTED; TUBERCULOSIS;

EID: 0033963683     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-200002000-00003     Document Type: Article

References (14)

1. Wahl RL: Clinical oncology update: The emerging role of positron emission tomography: Part 2. In: Devita VT, Hellman S, Rosenberg S, eds. Cancer Principles and Practice in Oncology, Fifth edition. Philadelphia: Lippincott-Raven Press, 1997, pp 1-24.
2. 18Fluoro-2-Deoxy-D-Glucose. J Comput Assist Tomog 17:582, 1993.
3. Yasuda S, Ide M, Takagi S, Setogawa T, Shohtsu A: Cancer screening whole-body FDG PET HIMEDIC imaging Centre at Lake Yamanaka, Yamanashi, Japan. In: Proceedings of the 8th Annual Meeting of the Institute for Clinical PET. Fairfax, VA: Institute for Clinical PET, 1996.
4. Nieweg OE, Kim EE, Wong WH, et al: Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 71:3920, 1993.
5. Jansson T, Westlin JE, Ahlstrom H, et al: Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation? J Clin Oncol 13:1470, 1995.
6. Avril N, Dose J, Janicke F, et al: Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 14:1848, 1996.
7. Wahl RL, Helvie MA, Chang AE, Anderson I: Detection of breast mass after augmentation mammoplasty using 18-Fluorodeoxyglucose-PET. J Nucl Med 35:872, 1994.
8. Adler LP, Crowe JP, Al-Kaisi N, Sunshine JL: Evaluation of breast masses and axillary lymph nodes with [F-18] 2-Deoxy-2-Fluoro-D-glucose PET. Radiology 187:743, 1993.
9. Engel H, Steinert H, Buck A, et al: Whole-body PET: Physiological and artifactual fluorodeoxyglucose accumulation. J Nucl Med 37:441, 1996.
10. Cook GJR, Fogelman I, Maisey MN: Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron emission tomography scanning: Potential for error in interpretation. Semin Nucl Med XXXVI:308, 1996.
11. Bakheet SM, Powe J: 18-FDG uptake due to benign pathology. Semin Nucl Med XXVIII:352, 1998.
12. Yasuda S, Fujii H, Takahashi W, et al: Lactating breast exhibiting high F-18 FDG uptake. Clin Nucl Med 23:767, 1998.
13. Avril N, Janicke F, Dose J, et al: FDG-PET in the assessment of suspecious breast tumor: Comparison with histology [Abstract]. J Nucl Med 35:222P, 1994.
14. Chiya Y, Kuwabara Y, Sasaki M, Yoshida T, Akashi Y, Murayama S, et al. FDG-PET in infectious lesions: The detection and assessment of lesion activity. Ann Nucl Med 10:185, 1996.